Kelly A. Romano Purchases 15,000 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) Stock

Athira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano acquired 15,000 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was acquired at an average price of $2.26 per share, for a total transaction of $33,900.00. Following the transaction, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Athira Pharma Stock Performance

ATHA stock opened at $2.64 on Friday. The firm has a market cap of $101.19 million, a P/E ratio of -0.87 and a beta of 2.91. The firm’s fifty day moving average is $2.36 and its 200 day moving average is $2.71. Athira Pharma, Inc. has a 52 week low of $1.33 and a 52 week high of $4.30.

Athira Pharma (NASDAQ:ATHA) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.11. As a group, analysts forecast that Athira Pharma, Inc. will post -2.79 EPS for the current year.

Institutional Trading of Athira Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATHA. Private Advisor Group LLC bought a new position in shares of Athira Pharma in the 4th quarter worth approximately $32,000. Mirador Capital Partners LP bought a new position in shares of Athira Pharma in the 1st quarter worth about $57,000. Forefront Analytics LLC lifted its position in Athira Pharma by 43.0% during the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after acquiring an additional 8,955 shares during the period. Clarius Group LLC boosted its stake in Athira Pharma by 35.8% during the fourth quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock worth $130,000 after acquiring an additional 14,124 shares in the last quarter. Finally, Laird Norton Trust Company LLC lifted its holdings in shares of Athira Pharma by 21.3% during the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after purchasing an additional 31,400 shares during the last quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and set a $19.00 price target on shares of Athira Pharma in a research report on Thursday, June 20th.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.